Salemonline Journal

DelveInsight’s Severe hypertriglyceridemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Severe hypertriglyceridemia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). 

The Severe hypertriglyceridemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Severe hypertriglyceridemia: Overview

Severe Hypertriglyceridemia refers to a fasting plasma triglyceride measurement that is increased, typically above the 95^th percentile for age and sex along with additional quantitative or qualitative lipoprotein abnormalities. Patients can fluctuate between hypertriglyceridemia states: given appropriate metabolic stress, mild or moderate hypertriglyceridemia can deteriorate into severe hypertriglyceridemia.

Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market 

Some of the key facts of the severe hypertriglyceridemia Market

• In the National Health and Nutrition Examination Survey (NHANES), from 1999 to 2004, about a third of participants had serum triglycerides above 150 mg/dL. In subjects aged 60 years or older, the prevalence was 42%, and 2% of subjects with hypertriglyceridemia had triglycerides of more than 500 mg/dL.
• According to Karanchi et al. (2019), the incidence of hypertriglyceridemia also varies by race, with a higher incidence observed in Hispanic-Americans and Asian-Indians, and lower incidence in African-Americans who generally have lower triglyceride levels. In addition, severe hypertriglyceridemia is the third leading cause of pancreatitis in the United States.
• The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) defined elevated triglycerides as 150 mg/dL and higher. Using that criterion, the Third National Health and Nutrition Examination Survey (NHANES) found that the prevalence of hypertriglyceridemia in US adults aged 20 years and older was approximately 35% in men and 25% in women.

Severe hypertriglyceridemia Market

Severe hypertriglyceridemia market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Severe hypertriglyceridemia in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Severe hypertriglyceridemia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Severe hypertriglyceridemia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

 Severe hypertriglyceridemia Market Outlook

Hypertriglyceridemia (HTG) is well known to be associated with severe diseases such as acute pancreatitis and cardiovascular disease. The treatment regimens include nutritional intervention, the use of anti-hyperlipidemic drugs, and therapeutic apheresis. Apheretic treatment is indicated in medical emergencies such as hypertriglyceridemic pancreatitis.

 Severe hypertriglyceridemia Treatment Market

The general treatment regimen for HTG includes dietary restrictions and lipid-lowering drug treatment such as the use of medium-chain triglycerides (MCT), fibrates, omega-3-fatty acids (omega-3-FA), and nicotinic acid. Yet, drugs of the first choice, such as fibrates, do not offer fast onset of action, while immediately acting drugs like omega-3-FA and MCT may not be powerful enough to lower excessively elevated TG levels rapidly. Since patients with excessively elevated TG levels are in urgent need of a fast and effective lowering of their TG levels to prevent a severe pancreatitis episode, further measures must be taken.

Severe hypertriglyceridemia Epidemiology

The epidemiology section covers insights about the historical and current Severe hypertriglyceridemia patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Severe hypertriglyceridemia Drugs & Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe hypertriglyceridemia market or expected to get launched in the market during the study period. The analysis covers Severe hypertriglyceridemia market uptake by drugs; patient uptake by therapies; and sales of each drug.

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Severe hypertriglyceridemia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Severe hypertriglyceridemia Therapeutics Analysis

Companies all over the globe are persistently working toward the development of new treatment therapies for Severe hypertriglyceridemia. The launch of the emerging therapies is expected to transform the treatment dynamics in the coming years. 

Severe hypertriglyceridemia Market Dynamics

The dynamics of the Hypertriglyceridemia (HTG) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and the expected launch of emerging therapies during the forecast period. Companies across the globe are thoroughly working towards the development of new treatment therapies for hypertriglyceridemia (HTG). Some of the key players in the therapeutic market of hypertriglyceridemia (HTG) at a global level are Regeneron Pharmaceuticals, Acasti Pharma, Arrowhead Pharmaceuticals and others. While some of the companies have recently shifted their focus towards this indication, yet others are expected to create a significant influence on the market size during the forecast period.

Severe hypertriglyceridemia Companies includes-

• AstraZeneca
• Amarin Pharma Inc.
• GlaxoSmithKline, and others

Severe hypertriglyceridemia Therapies includes-

• Epanova (omega-3-carboxylic acids)
• Vascepa
• Lovaza (omega-3-acid ethyl esters), and others

View Detailed Report of key players and therapies @ https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market 

Severe hypertriglyceridemia Market Drivers

• Increase in research activities
• Increasing disease prevalence
• The surge in the number of clinical studies

Severe hypertriglyceridemia Market Barriers

• Treatment costs
• Need for novel therapeutics
• Need for targeted treatment regimen

Read Full Research Report @ https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market

Table of content

1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis
4. Market Overview at a Glance
5. Disease Background and Overview
6. Patient Journey
7. Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Severe hypertriglyceridemia Treatment
11. Marketed Products
12. Emerging Therapies
13. Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/